Second line BCR/ABK TKI-associated severe adverse events:preferential occurrence in patients with comorbidities
Open Access
- 1 January 2011
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 96 (10), 1395-1397
- https://doi.org/10.3324/haematol.2011.052076
Abstract
Chronic myeloid leukemia (CML) is a hematopoietic neoplasm characterized by uncontrolled myeloproliferation, basophilia, and the BCR/ABL oncoprotein. The natural course of CML includes a chronic phase, an accelerated phase, and a blast phase that resembles an acute leukemia. The BCR/ABL tyrosine-This publication has 20 references indexed in Scilit:
- Severe Peripheral Arterial Disease During Nilotinib TherapyJNCI Journal of the National Cancer Institute, 2011
- Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinibHaematologica, 2011
- Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CMLAmerican Journal of Hematology, 2011
- Practical management of patients with chronic myeloid leukemiaCancer, 2011
- The effects of dasatinib on IgE receptor–dependent activation and histamine release in human basophilsBlood, 2008
- Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinibLeukemia Research, 2007
- Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targetsBlood, 2007
- Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemiaBlood, 2007
- Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib FailureJournal of Clinical Oncology, 2007
- New tyrosine kinase inhibitors in chronic myeloid leukemia.2005